Connect with us

Health

Europe Unlikely to Meet 2030 Hepatitis Elimination Goal, ECDC Warns

Published

on

Europe is unlikely to meet its target of eliminating viral hepatitis as a public health threat by 2030 despite years of progress in prevention and treatment, according to a new assessment by the European Centre for Disease Prevention and Control (ECDC).

The agency said improvements in vaccination, screening and treatment have reduced infections over the past two decades, but persistent gaps in childhood immunization and prevention programs continue to slow progress across the region.

“No one should die from a disease that is preventable, diagnosable and treatable, yet millions of Europeans are living with chronic hepatitis B or C infections, often without knowing it, which can lead to severe long-term consequences such as liver failure or liver cancer,” said Bruno Ciancio, Head of Unit for Directly Transmitted and Vaccine-Preventable Diseases at the ECDC.

Hepatitis B and hepatitis C are viral infections spread through infected blood or bodily fluids. Both diseases are major causes of chronic liver disease and can result in serious complications, including liver failure and cancer if left untreated.

According to the ECDC, an estimated five million people across Europe are living with chronic hepatitis B or C infections, while around 60,000 people die each year from liver diseases linked to the viruses.

Health officials noted that acute hepatitis B infections have steadily declined since 2006, reflecting the success of long-term vaccination campaigns and public health measures. Among people under the age of 25, the share of acute hepatitis B cases dropped from 11 percent in 2015 to 8 percent in 2024, demonstrating the positive impact of childhood immunization programs.

See also  E-Cigarette Use Rises as European Teens Turn Away from Alcohol and Drugs, Survey Finds

The report also highlighted progress in preventing transmission from mothers to newborns. Routine hepatitis B screening during pregnancy is now established across all 30 European Union and European Economic Area countries, helping reduce mother-to-child transmission to below 2 percent.

Despite these gains, the ECDC said vaccination coverage remains below international targets in many countries. Only a limited number of nations have achieved the World Health Organization’s goal of fully vaccinating 95 percent of children against hepatitis B, while some countries have reported declining immunization rates in recent years.

The agency also identified shortcomings in efforts to prevent hepatitis C among people who inject drugs. Measures such as opioid agonist treatment and the distribution of sterile needles and syringes have proven effective in reducing transmission, yet only seven countries currently meet the WHO target for providing sterile injection equipment.

Ciancio said the tools needed to control hepatitis already exist, including vaccination against hepatitis B, early testing, infection control measures and treatments that can cure hepatitis C and manage hepatitis B. He stressed that the challenge is ensuring these services are available to everyone who needs them.

The ECDC also pointed to shortcomings in monitoring prevention efforts aimed at reducing sexually transmitted hepatitis infections. While sexual transmission remains a significant route for hepatitis B and hepatitis C is commonly associated with injecting drug use and sex between men, the agency said targeted prevention programs are not being systematically tracked across European countries.

The findings suggest that stronger vaccination efforts, expanded harm reduction services and broader access to testing and treatment will be needed if Europe hopes to move closer to its hepatitis elimination goals in the coming years.

See also  Lead Pollution During Roman Empire May Have Contributed to Decline in IQ, Study Finds

Health

Portuguese Teenagers Report Lower Drug and Alcohol Use, but High-Risk Behaviour Persists

Published

on

Portuguese teenagers are reporting lower levels of alcohol and drug use and fewer problems linked to addictive behaviours, but risks are becoming increasingly concentrated among young people facing multiple personal and social difficulties, according to a new study.

The findings come from the 2024 Study on Alcohol, Tobacco, Drugs and Other Addictive Behaviours (ECATD-CAD), conducted by the Institute for Addictive Behaviours and Dependencies (ICAD). The research examines addictive behaviours among pupils aged 13 to 18 attending state schools across Portugal.

Compared with the previous study in 2019, the latest results show a consistent decline in reported problems, including violence, accidents, hospitalisations, risky sexual behaviour and other incidents with potentially serious consequences.

Researchers linked the broader improvement to several protective factors. Students reported better academic performance, closer parental supervision and fewer nights out, suggesting that changes in family and school environments may be helping reduce risky behaviour.

However, ICAD warned that the overall decline does not mean the problem has disappeared. The most serious behaviours are increasingly concentrated in a relatively small group of adolescents who face greater individual and social vulnerabilities.

Recent alcohol consumption and, particularly, illicit drug use remain strongly associated with problematic situations. Young people who use psychoactive substances report higher rates of risky sexual behaviour, violence between individuals, accidents and trouble with the police.

The report noted that these problems do not necessarily occur immediately after substance use, but the association remains significant.

Combining alcohol with illicit drugs appears to carry additional risks. Adolescents who reported recent use of both substances experienced higher levels of accidents, police-related problems, cyberbullying and risky sexual behaviour than those who consumed alcohol alone.

See also  E-Cigarette Use Rises as European Teens Turn Away from Alcohol and Drugs, Survey Finds

Alcohol use also raises concerns about why some teenagers drink. While pleasure, entertainment and socialising remain the main motivations, a significant proportion said they consumed alcohol to forget their problems. ICAD identified this as a warning sign associated with potentially harmful drinking patterns and dependence.

Cannabis use presented a mixed picture. Although most users showed no indicators of dependency risk, the proportion classified as being at high risk increased, alongside growth in the group with no identified risk.

Social media remained the main concern among behaviours not involving substances. A significant number of young people acknowledged spending excessive time on these platforms. Indicators of problematic electronic gaming remained broadly stable, while gambling for money became more prevalent among adolescents, despite a slight decline in some indicators of problematic gambling.

The study also identified differences between boys and girls. Boys were more likely to report problems with the police, risky gaming and gambling. Girls reported higher levels of problematic social media use and were more likely to use alcohol to cope with emotional difficulties.

Family circumstances and wellbeing were also important. Low academic achievement, limited parental supervision, frequent nights out and poorer physical and emotional health were associated with greater risk. Better school performance, stronger parental involvement and improved wellbeing appeared protective.

Regional differences were also evident. Alentejo recorded the highest concentration of unfavourable indicators, followed by the Azores. Lisbon, which showed the greatest vulnerability in the 2019 study, no longer held that position.

ICAD’s findings point to the need for targeted support for vulnerable adolescents, even as overall patterns of substance use and related problems improve.

Continue Reading

Health

Plague Fears Return After Russian Death, but Europe Faces Very Low Risk

Published

on

The death of a scientist in Russia’s Siberian region of Irkutsk has revived concerns about plague, but health authorities say there is currently no evidence of an outbreak or sustained transmission in Europe.

The woman died from pneumonia of unknown origin, prompting speculation that she could have contracted pneumonic plague. Russian authorities have said no plague cases have been confirmed in the region, while tests conducted on people who had contact with the woman were negative.

The World Health Organization has asked Russia for additional information about the incident and offered assistance to local health authorities.

Plague is caused by the bacterium Yersinia pestis, which remains present in wild animal populations in parts of the world. It is commonly associated with rodents and the fleas that live on them. People can become infected through bites from infected fleas, contact with tissues or bodily fluids from infected animals, or respiratory particles from people suffering from pneumonic plague.

For Spain and most of Europe, however, the current risk is considered very low. The European Centre for Disease Prevention and Control says routine transmission has not been recorded in Europe for more than five decades.

That does not mean the bacterium has disappeared. Its continued presence in animal reservoirs means isolated human infections remain possible, particularly in areas where infected wildlife and fleas are found.

Spain has maintained epidemiological surveillance despite the absence of locally acquired cases for decades. In April 2026, its Public Health Commission updated the national plague protocol, including case definitions, epidemiological information and procedures for investigating suspected infections.

See also  Rising Sea Temperatures Increase Risk of Vibrio Bacteria in European Coastal Waters

European authorities have also been monitoring the Siberian incident. The European Union discussed the case at a Health Security Committee meeting on October 7, while the ECDC said there was no evidence of secondary cases or sustained person-to-person transmission.

The WHO has assessed the risk to the European region as very low.

Plague continues to occur in parts of Africa, Asia and the Americas. According to the WHO, most reported human cases between 2019 and 2025 were concentrated in Madagascar and the Democratic Republic of the Congo. Madagascar records bubonic plague cases during its annual epidemic season, generally from September to April. In the United States, about seven human cases are reported each year, mainly in rural areas of western states.

The disease can occur in bubonic, pneumonic or septicaemic forms. Bubonic plague usually causes fever and painful swollen lymph nodes after an infected flea bite. Pneumonic plague affects the lungs and can spread between people through respiratory particles. Septicaemic plague occurs when the infection enters the bloodstream.

Modern antibiotics can successfully treat plague, but early diagnosis is critical. Health surveillance, rapid identification and treatment remain important in preventing isolated infections from developing into wider outbreaks.

Continue Reading

Health

Optogenetics Pioneers Win 2026 Nobel Prize in Medicine

Published

on

Scientists Karl Deisseroth, Peter Hegemann and Georg Nagel have been awarded the 2026 Nobel Prize in Physiology or Medicine for their work on light-gated ion channels and optogenetics, a technique that has transformed the study of the brain.

The Nobel Assembly at Karolinska Institutet announced the award on Monday, describing the work as laying the foundation for a new era in neuroscience.

Optogenetics allows researchers to control selected cells using light, effectively providing a remote switch that can turn specific cells on or off. The technique has enabled scientists to investigate how individual neurons and neural circuits influence behaviour in living animals.

The origins of the discovery date back to Hegemann’s research more than three decades ago. While studying the single-celled alga Chlamydomonas, which moves towards light, he sought to understand how the organism detects changes in illumination.

Hegemann focused on the alga’s eyespot, a small light-sensing structure on its surface. His research and subsequent experiments identified light-sensitive proteins known as channelrhodopsins.

Hegemann later worked with Nagel at the Max Planck Institute for Biophysics in Frankfurt. The researchers inserted genes from the algae into frog egg cells and human kidney cells, demonstrating that channelrhodopsin functions as a light-controlled ion channel.

When exposed to blue light, the channel can open within about 0.2 milliseconds. Positively charged ions then enter the cell, generating an electrical signal.

Deisseroth later adapted the discovery for neuroscience. He introduced the channelrhodopsin gene into rat nerve cells and showed that blue light could activate the cells and trigger nerve signals.

He subsequently used the technique in the brains of living mice, demonstrating that researchers could control specific groups of neurons with light. Experiments showed that stimulating selected neural circuits could produce physical responses, including movements of a mouse’s whiskers, or cause sleeping animals to wake.

See also  WHO Urges Global Overhaul of School Food to Combat Childhood Obesity

The method was named optogenetics in 2006 and has since become an important research tool in neuroscience.

Researchers now use it to establish direct links between neural activity and behaviour. By activating or silencing particular groups of cells, scientists can study circuits associated with fear, anxiety, reward, pain, thirst, attention and aggression.

The technique has also been used in research into conditions including depression, schizophrenia, anxiety, Alzheimer’s disease, Parkinson’s disease and epilepsy.

Per Svenningsson, chair of the Nobel Committee for Physiology or Medicine, said the discovery provides opportunities to map the brain in ways researchers could previously only imagine.

Optogenetics has also moved beyond laboratory research. Scientists are testing its potential as a treatment for retinitis pigmentosa, a genetic disorder that causes blindness through the loss of light-sensitive retinal cells.

In experimental treatments, researchers introduce genes encoding light-sensitive proteins into surviving retinal cells. In some trials, patients using specialised light-emitting goggles have been able to regain partial vision and detect high-contrast objects.

The Nobel award recognises a discovery that has given researchers an unprecedented way to investigate the relationship between brain cells, neural circuits and behaviour.

Continue Reading

Trending